Back

PRIME Education, Inc. (PRIME®)

  • Prostatic Neoplasms

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Management of metastatic hormone-sensitive prostate cancer (mHSPC) is becoming increasingly nuanced as biomarker-based approaches refine patient selection and therapeutic sequencing. In this second of three video podcasts recorded during a live satellite symposium at the American Society of Clinical Oncology (ASCO) Genitourinary Symposium 2026, two nationally recognized experts will explore the latest clinical evidence for emerging biomarkers and novel targeted therapy combinations in mHSPC. You will also explore multidisciplinary strategies for adverse event monitoring and proactive toxicity management to help optimize patient outcomes. An accompanying TheraFAQ Reference Guide is also available to download and reference in your daily practice

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.75 creditsAAPA Category 1 Credit™Up to 0.75 creditsAMA PRA Category 1 Credit™Up to 0.75 creditsNursingUp to 0.75 creditsPharmacyUp to 0.75 credits

MOC types

ABIM — Medical KnowledgeUp to 0.75 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Podcast / audio
  • includes Article / monograph / reference
  • includes On-demand / recorded video
  • Credit · Up to 0.75 credits
  • MOC · Up to 0.75 points
  • Commercial Support
  • Released
    Mar 26, 2026
  • Last day to claim credit
    Mar 26, 2027 5 months left